Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Vedolizumab IV in Pediatric Ulcerative Colitis or Crohn's Disease
2021-000630-34Phase 3Active
- Sponsor
- Takeda
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vedolizumab in autoimmune colitis and Crohn's disease, sponsored by Takeda. Primary endpoint: Adverse events. Started Sep 2022; status: active.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2021-000630-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000630-34.